Skip to main content
Category

Research

OncLive
ResearchTreatments

Dato-DXd Significantly Improves PFS in Select Subsets of Advanced/Metastatic NSCLC

*October 2023* Take home message: Comparison Dato-DXd, a novel TROP2-directed antibody-drug conjugate, to docetaxel in pretreated advanced/metastatic non-small cell lung cancer (NSCLC) patients, revealing significantly improved progression-free survival with Dato-DXd, especially in non-squamous histology patients, while demonstrating a manageable safety profile and ongoing evaluation of overall survival. (From OncoAlert) The Trop-2…
laurabbook@gmail.com
December 27, 2023
journal of clinical oncology logo
ResearchTreatments

A Phase 3, Randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR or ALK mutated in non-small cell lung cancer (ATTLAS, KCSG-LU19-04)

*October 2023* PURPOSE In the treatment of non-small cell lung cancer (NSCLC) with a driver mutation, the role of anti-PD-(L)1 antibody following tyrosine kinase inhibitor (TKI) remains unclear. This randomized, open-label, multicenter, phase 3 study evaluates the efficacy of atezolizumab plus bevacizumab, paclitaxel and carboplatin (ABCP) in EGFR or ALK-mutated NSCLC that progressed…
laurabbook@gmail.com
December 24, 2023
OncLive
ResearchTreatments

Trastuzumab Deruxtecan Wins EU Approval for HER2-Mutated Advanced NSCLC (DESTINY-Lung02 trial)

*October 2023* The European Commission (EC) has approved fam-trastuzumab deruxtecan-nxki (Enhertu) for the treatment of patients with advanced non–small cell lung cancer (NSCLC) whose tumors harbor an activating HER2 mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.1 The regulatory decision was supported by data from the phase…
laurabbook@gmail.com
December 24, 2023
Targeted Oncology
ResearchTreatments

EGFR Exon 20-Insertion NSCLC Population Sees PFS Benefit from Amivantamab/Chemotherapy (PAPILLON Trial)

*October 2023* Take home message: Amivantamab in combination with chemotherapy showed significantly improved PFS and a higher response rate compared to chemotherapy alone in treatment-naive patients with advanced non-small-cell lung cancer harboring EGFR exon 20 insertions, demonstrating its efficacy as a first-line treatment. The phase 3 PAPILLON trial (NCT04538664) resulted in…
laurabbook@gmail.com
December 24, 2023
Onc Live
ResearchTreatments

Osimertinib Plus Chemo Improves CNS PFS in EGFR+ Advanced NSCLC With Baseline Brain Metastases

*October 2023* Osimertinib (Tagrisso) plus chemotherapy reduced the risk of central nervous system (CNS) disease progression or death vs osimertinib alone in patients with locally advanced or metastatic EGFR-positive non–small cell lung cancer (NSCLC) who had brain metastases at baseline, according to data from the phase 3 FLAURA2 trial (NCT04035486) presented…
laurabbook@gmail.com
December 24, 2023
MEDPAGE TODAY
ResearchTreatments

New Options Challenge Standard Treatments in EGFR-Mutant NSCLC (MARIPOSA and MARIPOSA-2 Trials)

*October 2023* Take home message: In 1L setting, combo of Amivantamab (ami), an EGFR-MET bispecific antibody, and Lazertinib (laz), a CNS-penetrant 3rd-generation EGFR TKI, was evaluated against Osimertinib (osi) in the MARIPOSA study (NCT04487080) for treatment-naïve, EGFR-mutated locally advanced or metastatic NSCLC. After a median follow-up of 22.0 months, ami+laz…
laurabbook@gmail.com
December 24, 2023
Dr Christine Bestvina
ResearchStories

Clinician Spotlight: Dr. Christine Bestvina

*November 2023* This month, we are honored to feature Dr. Christine Bestvina, Assistant Professor at the University of Chicago Medicine Comprehensive Cancer Center, specializing in thoracic oncology. Dr. Bestvina has been connected with the EGFR Resisters since she was a fellow at University of Chicago! She participated in the first…
laurabbook@gmail.com
December 24, 2023
lungevity
FundingResearch

Drs. Susumu Kobayashi and Alexandre Reuben Announced as Recipients of EGFR Resisters/LUNGevity Research Award

*November 2023* WASHINGTON, DC (November 1, 2023) – LUNGevity Foundation, the nation’s leading lung cancer-focused nonprofit organization, is thrilled to announce the recipients of the EGFR Resisters/LUNGevity Research Award for EGFR-Positive Lung Cancer. EGFR Resisters, a vibrant patient-led community advocating for improved treatment options for patients with EGFR-positive lung cancer,…
laurabbook@gmail.com
December 24, 2023
PR Newswire
ResearchTreatments

Landmark Phase 3 MARIPOSA Study Meets Primary Endpoint Resulting in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival for RYBREVANT® (amivantamab-vmjw) plus Lazertinib Versus Osimertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer

*September 2023* RARITAN, N.J., Sept. 28, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive topline results from the Phase 3 MARIPOSA study evaluating RYBREVANT® (amivantamab-vmjw), a bispecific antibody targeting epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET), in combination with lazertinib, an oral third-generation EGFR tyrosine kinase…
laurabbook@gmail.com
December 24, 2023